Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.58 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190336 | 0.88 | PIK3CD (0.86) | PIK3CDPIK3CAPIK3R1 | |
| SCHEMBL2576576 | 0.86 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3R1 | |
| SCHEMBL13050685 | 0.81 | PIK3CD (0.71) | PIK3CDPIK3CA | |
| SCHEMBL190063 | 0.81 | PIK3CA (0.58) | PIK3CDPIK3CAPIK3R1 | |
| SCHEMBL28604999 | 0.80 | PIK3CD (0.87) | PIK3CDPIK3CA | |
| SCHEMBL2673524 | 0.79 | PIK3CD (0.73) | PIK3CDPIK3CA | |
| SCHEMBL14266921 | 0.79 | PIK3CD (0.46) | PIK3CDPIK3CA | |
| SCHEMBL1680075 | 0.79 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3R1 | |
| SCHEMBL2675377 | 0.79 | PIK3CD (0.70) | PIK3CDPIK3CA | |
| SCHEMBL2674154 | 0.79 | PIK3CD (1.00) | PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802670-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802670-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CA 1/4885PIK3R1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.